HTG MOLECULAR DIAGNOSTICS IN's ticker is HTGM and the CUSIP is 40434H104. A total of 18 filers reported holding HTG MOLECULAR DIAGNOSTICS IN in Q4 2017. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2017 | $17,000 | – | 10,169 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Stonepine Capital Management, LLC | 2,675,889 | $6,797,000 | 5.97% |
PERKINS CAPITAL MANAGEMENT INC | 449,950 | $1,143,000 | 0.89% |
Diametric Capital, LP | 116,754 | $297,000 | 0.23% |
Granahan Investment Management | 924,300 | $2,348,000 | 0.17% |
Requisite Energy Fund I LP | 100,000 | $254,000 | 0.10% |
Requisite Capital Management, LLC | 100,000 | $254,000 | 0.10% |
B. Riley Wealth Advisors, Inc. | 250,000 | $635,000 | 0.09% |
Kalos Management, Inc. | 74,420 | $179,000 | 0.09% |
Crow Point Partners, LLC | 65,475 | $164,000 | 0.03% |
ARDSLEY ADVISORY PARTNERS LP | 35,000 | $89,000 | 0.02% |